CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 110 enrolled
Drug / intervention
InterStim Basic Evaluation lead and foramen needledevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04016324
NCT04016324N/ACompleted

InterStim Basic Evaluation Lead Post Market Clinical Follow-Up Study

MedtronicNeuro·interventional·Posted Jul 11, 2019·Updated Nov 23, 2021

In Brief

A clinical study evaluating InterStim Basic Evaluation lead and foramen needle for Overactive Bladder and 2 related conditions. Completed, enrolled 110 participants across 15 sites in 4 countries.

Detailed Summary

Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Netherlands, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 11, 2019
Enrollment StartNov 28, 2019
Primary CompletionOct 6, 2020
Study CompletionOct 9, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.0 years ago

Interventions

InterStim Basic Evaluation lead and foramen needledevice

Commercial devices within their intended use as described in approved Instructions for Use.